Calithera Biosciences, Inc.

136 articles with Calithera Biosciences, Inc.

• Final Data from Calithera Biosciences’ Phase 2 CANTATA Study in Renal Cell Carcinoma Presented at 2021 ASCO Annual Meeting

  6/7/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), today shared final results from the Phase 2 CANTATA study evaluating the company’s glutaminase inhibitor telaglenastat (CB-839).

• Calithera to Present at the Jefferies 2021 Virtual Healthcare Conference

  5/27/2021

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the Jefferies 2021 Virtual Healthcare Conference on Friday, June 4, 2021 at 9:00 am ET.

• Antengene and Calithera Biosciences Enter into Worldwide Exclusive License Agreement to Develop and Commercialize CD73 Inhibitor CB-708 (ATG-037)

  5/17/2021

  --Antengene to lead development and commercialization of CD73 inhibitor CB-708 (ATG-037) worldwide --Calithera will receive an upfront payment，potential milestones and tiered royalties

• Calithera Biosciences Reports First Quarter 2021 Financial Results and Recent Highlights

  5/6/2021

  Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel, small molecule drugs for the treatment of cancer and other life-threatening diseases, announced its financial results for the first quarter ended March 31, 2021.

• Calithera Biosciences to Report First Quarter 2021 Financial Results on Thursday, May 6, 2021

  4/30/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s first quarter 2021 financial results will be released on Thursday, May 6, 2021.

• Results from Calithera Biosciences’ CANTATA Study to Be Presented at 2021 ASCO Annual Meeting

  4/28/2021

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, announced that final results from the CANTATA clinical study will be shared in an oral presentation at the American Society of Clinical Oncology 2021 Annual Meeting taking place virtually June 4-8, 2021.

• Calithera Biosciences Reports Fourth Quarter 2020 Financial Results and Recent Highlights

  3/16/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced today its financial results for the fourth quarter ended December 31, 2020. As of December 31, 2020, cash, cash equivalents and investments totaled $115.2 million.

• UPDATE – Calithera Biosciences to Report Fourth Quarter 2020 Financial Results on Tuesday, March 16, 2021

  3/12/2021

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that the Company’s fourth quarter 2020 financial results will be released on Tuesday, March 16, 2021.

• Calithera Biosciences to Report Fourth Quarter 2021 Financial Results on Tuesday, March 16, 2021

  3/10/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that the Company’s fourth quarter 2020 financial results will be released on Tuesday, March 16, 2021.

• Calithera to Present at the H.C. Wainwright Virtual Global Life Sciences 2021 Conference

  3/2/2021

  Calithera Biosciences, Inc., a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright Virtual Global Life Sciences Conference.

• Calithera to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

  2/22/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will participate in a fireside chat at the SVB Leerink Global Healthcare Conference at 1:40 p.m. ET on Friday, February 26, 2021.

• INCB001158 Biliary Tract Cancer Data to be Presented at 2021 Virtual ASCO Gastrointestinal Cancers Symposium

  1/11/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that preliminary safety and efficacy data from a trial evaluating the arginase inhibitor INCB001158, which is being developed by Incyte Pharmaceuticals, will be presented in a virtual poster session at the

• 

  Clinical Catch-Up: January 4-8

  1/11/2021

  The new year began with a fairly low level of clinical trial news. Here’s a look.

• Calithera to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference

  1/5/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chief executive officer, will present at the H.C. Wainwright VIRTUAL BioConnect Conference. The presentation will be available on January 11

• 

  Calithera Cutting 35% of Workforce After Kidney Cancer Trial Failure

  1/4/2021

  Calithera Biosciences reported that its CANTATA clinical trial of telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC) failed to hit the primary endpoint.

• Calithera Biosciences Reports CANTATA Study of Telaglenastat in Renal Cell Carcinoma Did Not Achieve Primary Endpoint

  1/4/2021

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small-molecule drugs for the treatment of cancer and other life-threatening diseases, today announced topline results from the CANTATA clinical study of the company’s glutaminase inhibitor telaglenastat in patients with advanced or metastatic renal cell carcinoma (RCC)

• Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 31, 2020

  12/31/2020

  Calithera Biosciences, Inc. announced that the compensation committee of the company’s board of directors granted one new employee a non-qualified stock option to purchase an aggregate of 50,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on December 31, 2020.

• Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 02, 2020

  12/2/2020

  Calithera Biosciences, Inc announced that the compensation committee of the company’s board of directors granted three new employees a non-qualified stock option to purchase an aggregate of 53,000 shares of Calithera’s common stock, at a per share exercise price of $4.91, the closing trading price on November 30, 2020.

• Calithera to Participate in Jefferies Virtual Healthcare Conference and SVB Leerink Oncology 1x1 Day

  11/11/2020

  Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced its participation at two upcoming healthcare investor conferences in November.

• Calithera Biosciences Presents New Preclinical Data for CB-668 at Society for Immunotherapy of Cancer (SITC) 2020 Annual MeetingIL4I1 inhibitor shows immune-mediated anti-tumor activity

  11/9/2020

  Calithera Biosciences, Inc., a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, announced that new preclinical data for the company’s novel IL4I1 inhibitor CB-668 will be presented at the Society for Immunotherapy of Cancer Virtual Annual Meeting 2020.